Liaoxian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a controlled active pharmaceutical ingredient powder supplied as a homogeneous solid for downstream dosage-form manufacture. The material is identified by the product designation Liaoxian Powder; no separate model number is assigned in the current technical documentation. It is intended exclusively for formulation by veterinary pharmaceutical manufacturers and not for direct administration. The powder is characterized by lot-specific particle size distribution, bulk and tapped density, loss on drying, residue on ignition, heavy metals, assay, related substances, residual solvents, and microbial limits. The target particle size distribution is typically controlled to support uniform dispersion in dry blends, wet granulations, and liquid preparation; exact D90 values vary with the intended finished dosage form. For direct compression and capsule filling, sieved fractions are often specified with D90 in the range of 75 µm to 150 µm; for injectable preparations, the powder is not a final sterile form and must undergo dissolution and sterilizing filtration. Bulk density may fall between 0.45 g/cm³ and 0.65 g/cm³, with tapped density between 0.55 g/cm³ and 0.80 g/cm³, but these values are subject to milling conditions and residual moisture. Because the powder can segregate in low-shear transfer lines, manufacturers should verify blend uniformity after any bin discharge, vacuum transfer, or screw feeder transfer. The material should be stored in sealed high-density polyethylene drums with desiccant, below 25 °C and 60% relative humidity; pre-drying is required if ambient relative humidity exceeds 60% and the powder is intended for direct compression. These storage and transfer controls are not required for feed-grade powders of the same active substance, and this distinction is material to finished-product quality.

What Pharmacopoeial Acceptance Criteria Govern the Veterinary-Grade Powder?

Liaoxian Powder is supplied as a veterinary API, and release parameters are drawn from the applicable veterinary pharmacopoeial monograph, the manufacturer's validated specification, and the finished-product dossier. Where a dedicated monograph is absent, general chapters of the European Pharmacopoeia, Chinese Veterinary Pharmacopoeia, or United States Pharmacopeia govern test methodology. Published data for this specific Liaoxian configuration is limited; therefore, the values below are category-level pharmacopoeial controls and should be confirmed against the batch certificate of analysis. Typical tests include appearance, identification by infrared absorption or retention time, assay by high-performance liquid chromatography, loss on drying, residue on ignition, heavy metals, residual solvents, related substances, microbial enumeration, and bacterial endotoxins where injectable use is claimed. The specification may adopt the following control intervals: assay 98.0% to 102.0% on the dried basis; loss on drying ≤ 5.0%; residue on ignition ≤ 0.1%; heavy metals ≤ 20 mg/kg; total aerobic microbial count ≤ 10³ CFU/g and total combined yeasts/molds count ≤ 10² CFU/g for non-sterile oral powders under Ph. Eur. category 3B. For injectable-grade use, bacterial endotoxins are typically set at ≤ 0.50 EU/mg unless the finished product requires a lower limit. Residual solvents are evaluated by headspace gas chromatography using Ph. Eur. 2.4.24 or USP <467>; Class 2 solvents are limited to the option 2 concentration thresholds unless otherwise justified. Heavy metals may be determined by inductively coupled plasma mass spectrometry after closed-vessel digestion, and individual metal limits for lead, cadmium, mercury, and arsenic are adopted from the applicable pharmacopoeia. The release specification is therefore not a single static value but a route-dependent control set. A representative control matrix is summarised below.

The actual certificate of analysis supersedes this category matrix. For injectable dosage forms, the manufacturer must also verify that the selected solubility-enhancing excipient does not introduce particulate matter or extractable impurities above the patient-specific safety margin.

Dry blending of Liaoxian Powder into premix, granule, or powder bases is controlled by particle-size overlap, charge retention, and mixer geometry. Low-shear tumble blenders such as V-blenders and bin blenders are acceptable when the formulation components have similar median particle sizes and the API concentration is not below 1.0% w/w; below this level, geometric pre-blending or high-shear granulation is required to avoid content uniformity failure. Powder flow is routinely assessed by angle of repose and Carr compressibility index; an angle of repose below 40° and a Carr index below 25 indicate acceptable flow for capsule filling and tableting. Values above these thresholds necessitate granulation, glidant addition, or conditioning at controlled relative humidity. In fluid-bed granulation, inlet air temperature is typically limited to 50 °C to 60 °C to prevent amorphous conversion or moisture-induced agglomeration; the exact limit depends on the thermostability of the active substance. Blending time must be validated because over-blending of lubricated formulations can increase magnesium stearate coverage and reduce tablet tensile strength. For premix applications intended for feed incorporation, a 1:10 to 1:100 stepwise dilution is used to achieve homogeneous distribution in a ribbon mixer or horizontal paddle mixer. At production scale, electrostatic charging of the API has been observed during vacuum transfer; static dissipative hoses and controlled relative humidity below 50% reduce wall adhesion and assay loss at transfer points. If the API is milling-sensitive, jet milling should be preferred over hammer milling because the latter can generate enough heat to increase amorphous content and alter dissolution kinetics. These process boundaries are specific to the API grade and are not controlled in ordinary feed-grade or technical-grade supply chains.

Injectables, Solubility, and Endotoxin Control

Injectable dosage forms prepared from Liaoxian Powder require a dissolution step followed by clarification and sterilizing filtration. The primary powder itself is not sterile and must be treated as a non-sterile API unless validated terminal sterilization is applied. The dissolution vehicle is selected on the basis of saturation solubility and pH stability. If aqueous solubility is insufficient, the formulator may evaluate phosphate buffer at pH 6.8 to 7.4, propylene glycol, polyethylene glycol, or cyclodextrin inclusion; published data for this specific Liaoxian configuration is limited, so solubility screening should be conducted before batch manufacture. Solutions are pre-filtered through a 0.45 µm membrane and sterilized through a 0.22 µm membrane under aseptic conditions. The endotoxin limit for the API is meaningful only when converted to a finished-product limit; a typical control point for injectable APIs is ≤ 0.50 EU/mg by Ph. Eur. 2.6.14, but high-volume infusions or intrathecal products may require ≤ 0.25 EU/mg or lower. Insoluble particulate matter in the final solution is controlled by Ph. Eur. 2.9.19 or USP <788>; for small-volume parenterals, particle counts must not exceed 6000 particles per container at ≥ 10 µm and 600 particles per container at ≥ 25 µm based on the current harmonized limits. Filter compatibility is evaluated with polyvinylidene fluoride, polyethersulfone, and nylon membranes; surfactant or cosolvent systems may require a mixed cellulose ester compatibility check because of leachables. The API should not be combined with strong oxidising agents, amine-containing buffers, or acidic excipients without forced-degradation data, because solution degradation may increase related substances above the applicable threshold. Terminal sterilization by autoclaving at 121 °C for 15 minutes is possible only when the active substance is thermostable; otherwise, aseptic filtration is the preferred route. For multi-dose injectable formulations, an antimicrobial preservative is required, and its compatibility with the API must be confirmed by preservative effectiveness testing according to Ph. Eur. 5.1.3 or USP <51>. These injectable-specific controls are absent from feed-grade and technical-grade powders and represent a key product difference.

When Liaoxian Powder Is Compounded into Capsules or Tablets, What Process Boundary Conditions Apply?

In tableting, the API is typically dry-mixed with direct-compression diluents such as microcrystalline cellulose and dicalcium phosphate anhydrous, then lubricated with magnesium stearate at 0.5% to 2.0% w/w. Compression force is adjusted to achieve a tablet hardness of 40 N to 80 N for immediate-release tablets or 80 N to 120 N for small-diameter coated tablets, but the exact range depends on punch size and polymer matrix. Granulation is required when the API particle size is below 20 µm D50 or when dusting and poor flow occur. Wet granulation should not be used if the active substance is hydrolytically unstable; in such cases, dry granulation by roller compaction is preferred. Moisture content at compression should be maintained below 3.0% w/w, and blending rooms should be conditioned at 40% to 50% relative humidity. For capsule filling, the formulated blend is processed on a dosator or tamping-pin capsule machine; fill weight variation is controlled to ±5.0% at target and content uniformity to USP <905> or Ph. Eur. 2.9.40. Tablet friability should be ≤ 1.0% after 100 rotations in a friabilator according to USP <1216> or Ph. Eur. 2.9.7. On rotary tablet presses with 30 stations, lower punch die fill variation increases if bulk density drops below 0.40 g/cm³; a force feeder is required to maintain acceptable content uniformity. If the formulation contains a disintegrant such as croscarmellose sodium, wetting and disintegration times should be checked because low tablet porosity can extend disintegration beyond 15 minutes and delay release. Avoid combination with amine-based additives unless compatibility screening demonstrates no degradation; amide or ester active groups may undergo nucleophilic attack in the presence of amines and moisture.

Comparison Against Feed-Grade and Technical-Grade Powders

The veterinary API grade differs from feed-grade and industrial technical-grade powders in residue, microbiological, and particle engineering controls. Feed-grade powders may carry higher microbial loads and may be blended with carriers without full related-substance or residual-solvent testing. Technical-grade powders are not manufactured under pharmaceutical quality systems and may contain unidentified by-products or metal residues unsuitable for parenteral or oral pharmacotherapy. The table below outlines the control basis; individual lots must be assessed against the certificate of analysis.

In addition, the veterinary API grade is supported by change control, stability data, and batch-to-batch traceability under good manufacturing practice. This is the decisive operational difference when the same substance is offered as a feed additive or technical intermediate. The API grade is not interchangeable with feed-grade material without requalification because carrier systems may mask the absence of pharmaceutical controls until content uniformity or dissolution failure occurs. For purchasing departments, the critical evidence is not the product name but the certificate of analysis, test method validation, and the active pharmaceutical ingredient master file.

For oral solutions, drench concentrates, and drinking-water premixes, Liaoxian Powder is dissolved or dispersed in a vehicle, and clarity is evaluated after passage through a 75 µm screen and, where required, a 0.45 µm filter. The resulting product is then diluted to the prescribed concentration; dose uniformity is confirmed by high-performance liquid chromatography assay and content uniformity testing. In premix manufacture, the API is dispersed on a suitable carrier such as lactose monohydrate or precipitated silica, and homogeneity is verified at 10 sampling points with relative standard deviation not exceeding 5.0%. These operations should not be conducted with feed-grade or technical-grade material because the higher bioburden and unspecified impurities can alter stability and safety. Vehicle selection for oral solutions should include pH adjustment only after verifying that the active substance remains at or above 95% of label claim for the intended dosing interval. Antioxidants may be required if the molecule is subject to oxidative degradation; the choice is made by forced-degradation study rather than by assumption. Containers for multidose oral solutions should be light-resistant and fitted with a calibrated dosing device. For powder and granule sachets, filled weight tolerance is typically controlled to ±5.0% and moisture content to ≤ 3.0% to prevent caking. Because the powder is not a finished product, excipient compatibility data must be generated by the formulator before registration.